If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid ...

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...

The stock's fall snapped a four-day winning streak.

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a ...

The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...

If you appreciate the Mercury's interesting and useful news & culture reporting, consider making a small monthly contribution ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.